A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Eltrombopag | Aluminium can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levothyroxine | Aluminium can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminium. |
| Cefuroxime | The serum concentration of Cefuroxime can be decreased when it is combined with Aluminium. |
| Rifampin | Aluminium can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Memantine | Aluminium may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Quinidine | Aluminium may decrease the excretion rate of Quinidine which could result in a higher serum level. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Aluminium. |
| Tolevamer | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Aluminium. |
| Thiethylperazine | Aluminium can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Promazine | Aluminium can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prochlorperazine | Aluminium can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chlorpromazine | Aluminium can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Triflupromazine | Aluminium can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fluphenazine | Aluminium can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thioridazine | Aluminium can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Moricizine | Aluminium can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Trifluoperazine | Aluminium can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perphenazine | Aluminium can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mesoridazine | Aluminium can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acetophenazine | Aluminium can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Promethazine | Aluminium can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Alimemazine | Aluminium can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methotrimeprazine | Aluminium can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Periciazine | Aluminium can cause a decrease in the absorption of Periciazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acepromazine | Aluminium can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aceprometazine | Aluminium can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pipotiazine | Aluminium can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thioproperazine | Aluminium can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| BL-1020 | Aluminium can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cyamemazine | Aluminium can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylene blue | Aluminium can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Propiopromazine | Aluminium can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perazine | Aluminium can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Butaperazine | Aluminium can cause a decrease in the absorption of Butaperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chlorproethazine | Aluminium can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thiazinam | Aluminium can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dixyrazine | Aluminium can cause a decrease in the absorption of Dixyrazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perphenazine enanthate | Aluminium can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methenamine | The therapeutic efficacy of Methenamine can be decreased when used in combination with Aluminium. |
| Doxycycline | Aluminium can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lymecycline | Aluminium can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Clomocycline | Aluminium can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oxytetracycline | Aluminium can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Demeclocycline | Aluminium can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tetracycline | Aluminium can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Metacycline | Aluminium can cause a decrease in the absorption of Metacycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Minocycline | Aluminium can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sarecycline | Aluminium can cause a decrease in the absorption of Sarecycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Omadacycline | Aluminium can cause a decrease in the absorption of Omadacycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Penimepicycline | Aluminium can cause a decrease in the absorption of Penimepicycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pamidronic acid | The serum concentration of Pamidronic acid can be decreased when it is combined with Aluminium. |
| Zoledronic acid | The serum concentration of Zoledronic acid can be decreased when it is combined with Aluminium. |
| Alendronic acid | The serum concentration of Alendronic acid can be decreased when it is combined with Aluminium. |
| Ibandronate | The serum concentration of Ibandronate can be decreased when it is combined with Aluminium. |
| Clodronic acid | The serum concentration of Clodronic acid can be decreased when it is combined with Aluminium. |
| Risedronic acid | The serum concentration of Risedronic acid can be decreased when it is combined with Aluminium. |
| Etidronic acid | The serum concentration of Etidronic acid can be decreased when it is combined with Aluminium. |
| Tiludronic acid | The serum concentration of Tiludronic acid can be decreased when it is combined with Aluminium. |
| Incadronic acid | The serum concentration of Incadronic acid can be decreased when it is combined with Aluminium. |
| Ciprofloxacin | Aluminium can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nelfinavir | Aluminium can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Indinavir | Aluminium can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ritonavir | Aluminium can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Amprenavir | Aluminium can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tipranavir | Aluminium can cause a decrease in the absorption of Tipranavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Saquinavir | Aluminium can cause a decrease in the absorption of Saquinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Darunavir | Aluminium can cause a decrease in the absorption of Darunavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fosamprenavir | Aluminium can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lopinavir | Aluminium can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Asunaprevir | Aluminium can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| TMC-310911 | Aluminium can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Atazanavir | Aluminium can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rilpivirine | Aluminium can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Aluminium can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Palbociclib | The absorption of Palbociclib can be decreased when combined with Aluminium. |
| Dexmethylphenidate | Aluminium can cause a decrease in the absorption of Dexmethylphenidate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Erdafitinib | The risk or severity of adverse effects can be increased when Aluminium is combined with Erdafitinib. |
| Digoxin | The serum concentration of Digoxin can be decreased when it is combined with Aluminium. |
| Metildigoxin | The serum concentration of Metildigoxin can be decreased when it is combined with Aluminium. |
| Acetyldigoxin | The serum concentration of Acetyldigoxin can be decreased when it is combined with Aluminium. |
| Naproxen | Naproxen can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Aluminium. |
| Selpercatinib | The serum concentration of Selpercatinib can be decreased when it is combined with Aluminium. |
| Octreotide | Aluminium can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Estetrol | Aluminium can cause a decrease in the absorption of Estetrol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sotorasib | The therapeutic efficacy of Sotorasib can be decreased when used in combination with Aluminium. |
| Infigratinib | The serum concentration of Infigratinib can be decreased when it is combined with Aluminium. |
| Levoketoconazole | Aluminium can cause a decrease in the absorption of Levoketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Roxadustat | Aluminium can cause a decrease in the absorption of Roxadustat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolic acid | The serum concentration of Mycophenolic acid can be decreased when it is combined with Aluminium. |
| Sparsentan | The therapeutic efficacy of Sparsentan can be decreased when used in combination with Aluminium. |
| Vadadustat | The serum concentration of Vadadustat can be decreased when it is combined with Aluminium. |
| Nirogacestat | The serum concentration of Nirogacestat can be decreased when it is combined with Aluminium. |